Adeno-associated virus serotype 9 efficiently targets ischemic skeletal muscle following systemic delivery. - Wikidata - awgldk - TriplyDB

Adeno-associated virus serotype 9 efficiently targets ischemic skeletal muscle following systemic delivery.

Adeno-associated virus serotype 9 efficiently targets ischemic skeletal muscle following systemic delivery.

http://www.wikidata.org/entity/Q30414524

about

The potential of adeno-associated viral vectors for gene delivery to muscle tissue.Gene therapy for muscular dystrophy: moving the field forward.Systemic gene delivery following intravenous administration of AAV9 to fetal and neonatal mice and late-gestation nonhuman primates.Gene transfer of arginine kinase to skeletal muscle using adeno-associated virus.Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice.The role and regulation of erythropoietin (EPO) and its receptor in skeletal muscle: how much do we really know?Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges.Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy.NF-κB inhibition reveals a novel role for HGF during skeletal muscle repair.rAAV9 combined with renal vein injection is optimal for kidney-targeted gene delivery: conclusion of a comparative study.Rapid, scalable, and low-cost purification of recombinant adeno-associated virus produced by baculovirus expression vector system.A compact unc45b-promoter drives muscle-specific expression in zebrafish and mouse.The Gene Therapy Resource Program: A Decade of Dedication to Translational Research by the National Heart, Lung, and Blood Institute.Therapeutic Angiogenesis for Peripheral Artery Disease: Lessons Learned in Translational Science.

P2860

Q33902499-7CFB82F5-3858-49BE-807F-BB2E9D69A07D Q34625436-CFF00208-B1C2-4340-8B30-C2C69F55A43F Q36028204-F2CE9888-5C33-4EBB-98A5-BB555D485436 Q37684597-1BAA4814-1715-4B18-A56A-E2F675F40C96 Q37696030-0E9A7692-D36B-4934-8323-5E3987846BCE Q38123160-B12CAF89-9CBB-4331-9606-AE74B051848A Q38217461-1D4EAE75-CE04-4DFD-9C50-498B7D0505EC Q38338190-3A7A22AD-9AF1-462A-8C29-D41FEF5213DF Q38444259-03758B58-ED08-4B88-AC56-8E47AA63B188 Q40363311-1906EE0D-3DE9-4571-B990-12D56622C6F3 Q40735084-8D0A88B6-F8F6-4846-B869-AF53A1F97D8D Q42366746-488270DF-D57F-4BA6-BF3A-FC8FF3FF2E92 Q45874364-EEFACFA0-B3A7-4EAE-8A09-3AC1EC2F96B3 Q50072297-88CC7D47-772E-404A-9C38-392EE50D95A2

P2860

Adeno-associated virus serotype 9 efficiently targets ischemic skeletal muscle following systemic delivery.

http://www.wikidata.org/entity/Q30414524

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Adeno-associated virus serotyp ...... e following systemic delivery.

@ast

Adeno-associated virus serotyp ...... e following systemic delivery.

@en

type

label

Adeno-associated virus serotyp ...... e following systemic delivery.

@ast

Adeno-associated virus serotyp ...... e following systemic delivery.

@en

prefLabel

Adeno-associated virus serotyp ...... e following systemic delivery.

@ast

Adeno-associated virus serotyp ...... e following systemic delivery.

@en

P1433

Q30414524-75D42256-E99F-4768-9BB1-D72C2066410A

P1476

Q30414524-CA5AAA11-ADC6-4455-88AE-69F2A4C24CCA

P2093

Q30414524-0E3636B6-AF04-4D8D-9F3F-3D27EE7205F8

Q30414524-0E70409C-5A55-44D2-8326-279A12839CD8

Q30414524-187F661C-7298-44EB-ACD3-25D63CEFBE78

Q30414524-23EF3AB9-D0A7-44C4-9F78-3E30A8C4E154

Q30414524-2A98BBC7-956C-48E9-AE31-FD1228F5BE32

Q30414524-3E1CDDD4-69DF-4D82-BBC4-5F40F95D3246

Q30414524-5C0A5AF3-6777-4431-8D8A-AB101717B0C4

Q30414524-73F479E2-4927-4706-87D9-071BF419A414

Q30414524-9A4B851D-8401-4EB2-A22A-0BA49F5B22CE

Q30414524-D4229AB8-0FA7-45CC-BFE3-AD43DEDEA43E

P2860

Q30414524-007FB749-0044-4DDD-A785-5530044F3131

Q30414524-03495558-54C8-423E-BEFC-1FC2E50685CA

Q30414524-0935452C-40A1-4118-995E-7DB0F1A3860B

Q30414524-0BE8B9C3-1620-48B4-B06D-6360484C31B8

Q30414524-1864CC16-80AB-405A-A705-6030032117B6

Q30414524-196D68C9-3A62-4BF9-9708-DB7C9A35C5C7

Q30414524-1FC217E4-9C42-41D0-A78E-030EFFBCE593

Q30414524-34B8140C-135F-41FB-8F92-D42AFDB3D6CA

Q30414524-351F98F6-3C5E-47C4-8FEC-9501566D44FD

Q30414524-4CB60CB7-9E5F-4162-A2A2-A9C7F1830982

P2888

Q30414524-E178A1A9-0738-4061-A4EF-A62E8F6B76CC

P304

Q30414524-7D09B65A-84AF-4DBD-98DB-77E3C2768578

P31

Q30414524-70129EA5-FF60-48DF-9C2D-0B142235AC08

P356

Q30414524-A4E5DB9A-11DE-428E-9671-85B6EA5DD885

P433

Q30414524-8E6648BD-738A-470C-82BE-4B8C8516FCB7

P478

Q30414524-7EF1B3CE-BA95-4CBE-8BCA-C8C0C0CDCEE6

P50

Q30414524-0355AB63-3FA9-44A7-9506-F2C46AD50108

P577

Q30414524-0505F1D8-336D-467A-B9D8-D8E29D3C3CD4

P5875

Q30414524-8E64E4F7-4E32-4589-849E-80819BEF4F9C

P698

Q30414524-D49DAAFA-9F0F-4DBD-81E3-A787A8A140CA

P932

Q30414524-24BF0E17-2BC5-4263-A3B7-74C85142DE07

P356

P1433

P1476

Adeno-associated virus serotyp ...... le following systemic delivery

@en

P2093

A B Katwal

http://www.w3.org/2001/XMLSchema#string

B A French

http://www.w3.org/2001/XMLSchema#string

B H Annex

http://www.w3.org/2001/XMLSchema#string

E A Ferrante

http://www.w3.org/2001/XMLSchema#string

J M Sanders

http://www.w3.org/2001/XMLSchema#string

P R Konkalmatt

http://www.w3.org/2001/XMLSchema#string

R John Lye

http://www.w3.org/2001/XMLSchema#string

S Hazarika

http://www.w3.org/2001/XMLSchema#string

S S Li

http://www.w3.org/2001/XMLSchema#string

Z Yan

http://www.w3.org/2001/XMLSchema#string

P2860

Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model

Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps.

Peripheral arterial disease detection, awareness, and treatment in primary care

Focused ultrasound and microbubbles for enhanced extravasation.

Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution.

Topoisomerase inhibition accelerates gene expression after adeno-associated virus-mediated gene transfer to the mammalian heart.

In mice with type 2 diabetes, a vascular endothelial growth factor (VEGF)-activating transcription factor modulates VEGF signaling and induces therapeutic angiogenesis after hindlimb ischemia.

Fasting increases the in vivo gene delivery of AAV vectors.

Local gene transfer and expression following intramuscular administration of FGF-1 plasmid DNA in patients with critical limb ischemia.

A quantitative trait locus (LSq-1) on mouse chromosome 7 is linked to the absence of tissue loss after surgical hindlimb ischemia

P2888

P304

930-938

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/GT.2013.16

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236087357

http://www.w3.org/2001/XMLSchema#string

P698

23535898

http://www.w3.org/2001/XMLSchema#string

P932

3758463

http://www.w3.org/2001/XMLSchema#string